A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer

Xiao-Jiang Sun¹†, Qing-Hua Deng²†, Xin-Min Yu³, Yong-Lin Ji¹, Yuan-Da Zheng¹, Hao Jiang⁴, Ya-Ping Xu¹* and Sheng-Lin Ma²*

Abstract

Background: Endostatin inhibits the pro-angiogenic action of basic fibroblast growth factor and vascular endothelial growth factor in different human cancers. This study assessed the efficacy of endostatin combined with concurrent chemoradiotherapy of non-small cell lung cancer (NSCLC).

Methods: Nineteen patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0–1, and adequate organ function were treated with 60–66 Gy thoracic radiation therapy over 30–33 fractions concurrent with weekly 7.5 mg/m² endostatin for 14 days, 50 mg/m² paclitaxel, and 2 mg/mL/min carboplatin over 30 min. Patients were then treated with 7.5 mg/m² endostatin for 14 days, 150 mg/m² paclitaxel, and 5 mg/mL/min carboplatin every 3 weeks for 2 cycles as the consolidation treatment. The objective response rate was recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and the toxicity was evaluated using the National Cancer Institute (NCI) Common Toxicity Criteria.

Results: Six patients were unable to complete the consolidation treatment (4 pulmonary toxicity, 1 tracheoesophageal fistulae, and 1 progressive disease). Seventeen patients were included for data analysis. Specifically, one (5.9 %) patient had a complete response and 12 (70.6 %) had a partial response, whereas two patients had stable disease and the other two had disease progression. The overall response rate was 76 % (95 % CI, 51 %–97 %). The median progression-free survival was 10 months (95 % CI, 7.6–12.3 months), and the median overall survival was 14 months (95 % CI, 10.7–17.2 months). Early 10 patients who completed the treatment regimen showed that four patients experienced grade III pulmonary toxicity a few months after chemoradiotherapy, leading to the early closure of the trial according to the study design.

Conclusions: The result of concurrent endostatin treatment with chemoradiotherapy in locally advanced unresectable NSCLC did not meet the goal per study design with unacceptable toxicity. The real impact of endostatin as the first-line treatment combined with chemoradiotherapy on the survival of NSCLC patients remains to be determined. (NCT 01158144).

Keywords: NSCLC, Endostatin, Concurrent chemoradiotherapy, Clinical trial
Background
Lung cancer is the most significant worldwide health problem, and it accounted for 1.6 million new cancer cases and 1.4 million cancer-related deaths worldwide in 2008 [1]. Histologically, lung cancer can be classified primarily as small cell lung cancer or non-small cell lung cancer (NSCLC), and up to 85% of all lung cancer cases are NSCLC. To date, more than one-third of NSCLC cases are still diagnosed at the advanced stages of disease when curable surgery is no longer an option. A standard treatment for patients with inoperable locally advanced NSCLC is the use of concurrent chemoradiotherapy (CRT) [2, 3]. Clinically, chemoradiotherapy often fails to control NSCLC progression, and many patients die of recurrent disease. Thus, novel treatment strategies that effectively control NSCLC are urgently needed.

To this end, many research efforts have focused on developing novel treatment regimens to target tumor angiogenesis. Cancer tissues consist of a population of rapidly dividing and growing cancer cells, and to support tumor aggression, tumor cells secrete various growth factors [e.g., basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF)] to induce tumor angiogenesis in order to increase the supply of oxygen and other essential nutrients within tumor tissues [4]. Endostatin, a peptide identified in 1996, can specifically inhibit the activity of bFGF and VEGF to suppress tumor-related neovascular endothelial cells and induce cancer cell apoptosis [5]. A previous clinical trial has positively evaluated endostatin application in NSCLC [6]. Two additional randomized phase II studies in China also evaluated endostatin as the first-line therapy against advanced NSCLC and showed that endostatin together with platinum-based chemotherapy might increase response rates and prolong progression-free survival (PFS) and overall survival (OS) in NSCLC patients [7, 8]. Moreover, previous data on preclinical lung cancer models demonstrated that endostatin used as an adjuvant to radiation can significantly enhance the antitumor efficacy of radiotherapy in lung cancer cells [9, 10]. Taken together, previous studies have shown in vitro and in vivo that endostatin has anti-tumor activity as both an adjuvant and a concurrent treatment for different human cancers. Thus, in this phase II clinical trial, we assessed the efficacy of combined endostatin treatment with concurrent chemoradiotherapy on patients with unresectable stage III NSCLC.

Methods
Patient eligibility
The study protocol was approved by the institutional review board of Zhejiang Cancer Hospital (#200934) on September 1, 2009 and registered in ClinicalTrials.gov (#NCT01158144), May 13, 2010. Patients provided written informed consent to participate in this clinical trial and were informed of the investigational nature of the trial.

In this clinical study, we prospectively recruited 19 patients with unresectable stage IIIA or IIIB NSCLC between October 2009 and December 2011. All patients with NSCLC (16 squamous and 3 adenosquamous cell lung cancer) were histologically confirmed, and all patients had Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and adequate organ functions. Tumor lymph node metastasis was diagnosed by either histology, positron emission tomography with lymph node >0.5 cm in size, or computed tomography (CT) scan of 1-cm lymph nodes. The patients had no history of previous chemotherapy, radiotherapy, or surgical resection. Lung function of a forced expiratory volume in 1 s (FEV1) ≥1.5 L was also met, and the patients did not receive any full dose of anticoagulant or have any other pathologic conditions. None of the patients had a fine needle/core biopsy or mediastinoscopy within 7 days before treatment.

Treatment of patients
The detailed treatment plan is summarized in Fig. 1. All patients received the concurrent CRT regimen, i.e., chemotherapy consisting of weekly 50 mg/m² paclitaxel over 1 h, weekly 2 mg/mL/min carboplatin over 30 min, and 7.5 mg/m² endostatin over 3 h infusion between days 1 and 14 and between days 22 and 35. Radiation therapy was field arranged and determined by 3D or IMRT planning at the primary lesion and involvement of metastatic lymph nodes, and was prescribed at 60–66 Gy and given in 30–33 fractions at 200 cGy/day, 5 days a week without interruption. After 4–7 weeks of completion of radiation therapy, patients without progressive disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) were then given 150 mg/m² paclitaxel and 5 mg/mL/min carboplatin on day 1 and 7.5 mg/m² endostatin between days 1 and 14 every 3 weeks for two cycles as the consolidation treatment.

Toxicity evaluation and treatment modifications
In this clinical trial, we followed the National Cancer Institute (NCI) Common Toxicity Criteria version 3.0 to assess treatment-related toxicities and adverse events [http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm]. In brief, if the absolute granulocyte count was <1.5 × 10⁹/L, and/or the platelet count was <75 × 10⁹/L, chemotherapy was delayed. Dose delays up to 2 weeks from day 1 of the current cycle were permitted for recovery from adverse events. Paclitaxel and carboplatin infusion was recommened with a 25% dose reduction if patients experienced higher than grade II hematological toxicity during the previous treatment cycle. The dosages of paclitaxel and carboplatin were reduced to 50% if the patients
still suffered grade III hematological toxicity. A maximum of two dose reductions were permitted. Furthermore, granulocyte colony-stimulating factor at a dose of 5 μg/kg was recommenced for treating neutropenic events. Following the first dose of endostatin, toxicity was assessed weekly in all patients, and special attention was given to monitoring blood pressure, bleeding, cardiovascular events, esophagitis, and tracheoesophageal/bronchial fistulae. Modification of the endostatin dose due to drug toxicity could be made at the discretion of physicians. If one or more study drugs were discontinued, further treatment with the remaining drugs was allowed in the absence of disease progression.

**Patient evaluation and follow-up**

All patients were evaluated before participation in this clinical trial according to medical history, physical exam, PS, laboratory tests, pulmonary function test, EKG, and MRI or CT scan of the brain, chest, liver, and adrenal glands. During CRT and consolidation treatment, complete blood counts were assessed weekly. Patients’ history, physical exam results, and chemistries were re-assessed prior to each treatment cycle. Once endostatin was started, weekly toxicity assessment was required and continued until 60 days after discontinuation of endostatin or until all adverse events had resolved. Treatment response was assessed at the end of CRT and carboplatin/paclitaxel/endostatin consolidation treatment and then every 2–3 months for 2 years and every 6 months until 5 years.

**Statistical analyses**

This is a prospective phase II study at a single institution, and the primary end point of the trial was to evaluate the response rate and toxicity of this concurrent radiotherapy and chemotherapy regimen. The secondary end point was PFS and OS of the patients with unresectable locally advanced NSCLC. This clinical trial was designed to measure a response rate [complete responses (CRs) and partial responses (PRs)] of 85 % compared to a minimal, clinically meaningful response rate of 70 %. Using an alpha = 0.05 and a power of 80 %, the target number of patients required to achieve an 85 % CR plus PR rate was 20 patients according to a previous study [11].

Given the known risks of concurrent chemoradiotherapy, a toxicity analysis was planned after 10 patients had completed all treatment regimes. Toxicity was assessed as unacceptable if 4 or more of these 10 patients experienced at least grade III esophageal or pulmonary toxicity.

PFS was calculated from the day of initiation of treatment to the date of disease progression, death or until the last follow-up, whereas OS was calculated from the first day of CRT until death or until the last follow-up. The survival curves were calculated using the Kaplan–Meier method. The considered variables included: age, gender, histopathology, smoking status (cigarettes/year), and stage. All statistical analyses were performed using SPSS software, Version 19.0 (SPSS Inc., Chicago, IL).
**Results**

**Patient characteristics**

This study was opened in October 2009 and closed in December 2011 according to the protocol definition, i.e., early 10 patients who completed treatment, including four or more patients with at least grade III pulmonary toxicity a few months after the CRT, thus leading to the early closure of the trial according to the study design.

The characteristics of these 19 assessable patients are shown in Table 1. In brief, there were 16 patients with squamous cell carcinoma and a higher proportion of male patients with stage IIIB. Seventeen patients completed the CRT, whereas six patients were unable to complete the consolidation treatment (4 due to pulmonary toxicity, 1 due to tracheoesophageal fistulae, and 1 due to progressive disease).

**Treatment efficacy**

Nineteen patients had measurable disease at baseline. Response was not assessable in two (10.5 %) patients due to pulmonary toxicity and incompletion of the CRT as planned. The objective tumor response for targeted lesions was assessed and calculated 2–4 weeks after the concurrent therapy. Seventeen patients were included in data analysis. The overall response rate (CR + PR) was 76 % (95 % CI: 51 %–97 %), two (12 %) patients had stable disease, and two (12 %) patients had disease progression (Table 2).

With a median follow-up time of 36 months, the median PFS was 10.0 months (95 % confidence interval [CI]: 7.6–12.3 months), and the median OS was 14.0 months (95 % CI: 10.7–17.2 months; Fig. 2).

**Treatment toxicity**

Toxicities did occur during and after the concurrent CRT or the consolidation treatment (Table 3). Specifically, grades III or IV leukopenia or neutropenia was the most common toxicity, occurring in 21 % and 26 % of the patients, respectively. Moreover, 11 % patients developed Grade III/IV febrile neutropenia, 16 % patients had grade III or IV esophagitis, and 26 % (5 episodes) had grade III pneumonitis. In addition, there was one patient with treatment-related tracheoesophageal/bronchial fistulae (one patient developed grade III esophagitis during concurrent CRT and then developed tracheoesophageal/bronchial fistulae 19 days after the first cycle of consolidation treatment).

**Discussion**

Chemotherapy has been successfully incorporated with radiation to treat unresectable locally advanced NSCLC with an acceptable toxicity. However, the treatment outcome remains largely unsatisfactory, indicating that novel agents to additively or synergistically enhance the action of radiation against NSCLC are urgently needed. Thus, our current study determined the efficacy of combined endostatin treatment with concurrent chemoradiotherapy in patients with unresectable stage III NSCLC. We found that out of the 17 patients, 1 had a complete response and 12 had a partial response. Two patients had stable disease, and another two had disease progression. The median PFS was 10 months, and the median OS was 14 months. Early 10 patients who completed the treatment regimen showed that four patients experienced grade III pulmonary toxicity, leading to the early closure of the trial according to the study design. Thus, our current data showed that concurrent endostatin treatment with chemoradiotherapy in locally advanced unresectable NSCLC did not meet the goal per study design with unacceptable toxicity. The real impact of endostatin as the first-line treatment combined with chemoradiotherapy on the survival of NSCLC patients remains to be determined.

Currently, platinum-based CRT represents the standard treatment regime for locally advanced NSCLC patients, although the treatment efficacy is constrained by poor local

---

**Table 1** Characteristics of patients

| Characteristics | No. of patients (N = 19) |
|-----------------|---------------------------|
| **Age (years)** |                           |
| Median          | 58                        |
| Range           | 36–65                     |
| <60 years       | 10                        |
| ≥60 years       | 9                         |
| **Gender**      |                           |
| Male            | 16                        |
| Female          | 3                         |
| **Cigarettes/year** |              |
| ≥400            | 15                        |
| Never smoked    | 4                         |
| **Histology**   |                           |
| SCC             | 16                        |
| ADC             | 3                         |
| **UICC stage**  |                           |
| IIIA            | 5                         |
| IIIB            | 14                        |

**Table 2** Treatment efficacy in patients (N = 17)

| Treatment efficacy | No. of patients | %   |
|--------------------|-----------------|-----|
| **Response**       |                 |     |
| Overall response   | 13              | 76.4|
| Disease control    | 15              | 88.2|
| Complete response  | 1               | 5.9 |
| Partial response   | 12              | 70.6|
| Stable disease     | 2               | 11.7|
| Progressive disease| 2               | 11.7|
| **Survival**       |                 |     |
| Median PFS (months)| 10.0 (95 % CI: 7.6–12.3 months) |
| Median OS (months) | 14.0 (95 % CI: 10.7–17.2 months) |
control and radiation-induced lung injury (RILI). To improve the effect of the platinum-based CRT on NSCLC, a number of clinical trials have been conducted, but similar to our current study, the results suggest that the concomitant treatment of patients with unresectable locally advanced NSCLC with endostatin, paclitaxel/carboplatin, and radiotherapy does not show a significant clinical value. The present study indicated that the overall response rate (76%; 95% CI: 51%–97%) did not exceed the goal per study design (85.0%), and the toxicity analysis after 10 patients had completed treatment indicated that four patients had grade III pulmonary toxicity. With a median follow-up time of 36 months, the median PFS was 10 months, and the median OS was 14 months. Similar results were reported by another phase II study which assessed the activity and safety of weekly paclitaxel/carboplatin vs. cisplatin/etoposide based CRT for patients with unresectable IIIA/IIIB NSCLC. The overall response rates (CR + PR) were 81.3% in the paclitaxel/carboplatin arm. With a median follow-up time of 46 months, the median OS was 13.5 months (95% CI, 8.3–18.7 months) in the paclitaxel/carboplatin group [12].

Furthermore, endostatin is a 20-kDa COOH-terminal proteolytic fragment derived from the basement membrane component of collagen XVIII. Endostatin is one of the most potent inhibitors of angiogenesis. It was originally identified from the supernatant of a murine hemangioendothelioma cell line as an inhibitor of proliferation of endothelial cell proliferation and of angiogenesis [13–15]. Indeed, several in vitro and in vivo studies demonstrated that endostatin may potentiate radiation [9, 10]. Thus, endostatin was designed as a rational therapeutic agent combined with CRT for treatment of unresectable locally advanced NSCLC. However, endostatin has toxicity concerns and may cause development of tracheoesophageal/bronchial fistulae in NSCLC patients, but this is generally an uncommon event resulting from CRT of lung cancer. In a simultaneous and ongoing study in limited stage SCLC, among 29 patients there were 2 confirmed and 1 suspected episode of

Table 3 Toxicity profile after treatment

| Complications                  | 0    | I    | II   | III  | IV   | III + IV |
|--------------------------------|------|------|------|------|------|----------|
|                                | % (n) | % (n) | % (n) | % (n) | % (n) | % (n)    |
| Hematological toxicities       |      |      |      |      |      |          |
| Anemia                         | 32 (6)| 26 (5)| 32 (6)| 11 (2)| 0    | 11 (2)   |
| Leukopenia                     | 21 (4)| 32 (6)| 26 (5)| 16 (3)| 5 (1) | 21 (4)   |
| Neutropenia                    | 16 (3)| 32 (6)| 26 (5)| 21 (4)| 5 (1) | 26 (5)   |
| Thrombocytopenia               | 26 (5)| 42 (8)| 21 (4)| 5 (1) | 5 (1) | 11 (2)   |
| Non-hematological toxicities   |      |      |      |      |      |          |
| Nausea                         | 37 (7)| 37 (7)| 16 (3)| 11 (2)| 0    | 11 (2)   |
| Vomiting                       | 47 (9)| 32 (6)| 11 (2)| 11 (2)| 0    | 11 (2)   |
| Anorexia                       | 53 (10)| 26 (5)| 11 (2)| 5 (1) | 5 (1) | 11 (2)   |
| Hemorrhage                     | 90 (17)| 5 (1) | 5 (1) | 0     | 0    | 0        |
| Fatigue                        | 37 (7)| 32 (6)| 26 (5)| 5 (1) | 0    | 5 (1)    |
| ALT/AST                        | 89 (15)| 16 (3)| 5 (1) | 0     | 0    | 0        |
| Arrhythmia                     | 63 (12)| 37 (7)| 0    | 0     | 0    | 0        |
| Esophagitis                    | 26 (5)| 37 (7)| 16 (4)| 11 (2)| 5 (1) | 16 (3)   |
| Pneumonitis                    | 21 (4)| 26 (5)| 26 (5)| 26 (5)| 0    | 26 (5)   |
tracheoesophageal/bronchial fistulae [16, 17]. All 3 patients had grade III esophagitis during CRT and bevacizumab treatment (another tumor angiogenesis inhibitor that is a humanized monoclonal antibody directed against VEGF). Subsequently, an additional patient developed a fatal tracheoesophageal/bronchial fistula during maintenance treatment. In an independent study of NSCLC treatment, 2 of 5 patients developed tracheoesophageal/bronchial fistulae during maintenance treatment with chemotherapy and bevacizumab [17]. Both patients also had severe esophageal toxicity after CRT and bevacizumab. Therefore, together these results imply that severe esophageal toxicity as a result of this treatment may predispose patients to the development of tracheoesophageal/bronchial fistulae. In the Socinski trial, the rate of grade III/IV esophagitis was 29 %, and one case of tracheoesophageal/bronchial fistulae developed 3 months after CRT [18]. One patient in our study developed grade III esophagitis during concurrent CRT and then developed tracheoesophageal/bronchial fistulae 19 days after the first cycle of consolidation treatment. Thereafter, our study was amended to exclude patients with grade III or higher esophagitis from receiving endostatin. There were no cases of tracheoesophageal/bronchial fistulae in two previously randomized phase II studies in China in which endostatin was given with platinum-based chemotherapy as first-line treatment [7, 8].

However, our current data showed that it was difficult to ascertain whether addition of endostatin was efficacious in treating these patients and whether there was a synergy of endostatin plus radiation therapy. The median PFS and OS estimated at 10 and 14 months, respectively, were similar to those of previous clinical trials of CRT alone [1, 2, 4–6, 10, 16]. Whether the inconsistent schedule of endostatin from other studies made our work unsuccessful is worthy of more research. Our current study is also limited by a small study population, and a future study with more patients could help us to clarify the effects of endostatin on patients with unresectable locally advanced NSCLC.

Conclusion
We were unable to successfully integrate endostatin into concurrent CRT for unresectable locally advanced NSCLC because of safety, and the data are insufficient to determine efficacy. There are numerous new molecularly targeted agents that are of interest in the treatment of NSCLC. Careful study design and close toxicity monitoring is imperative to properly integrate their use in multimodality therapy.

Abbreviations
bFGF: basic fibroblast growth factor; CRT: chemoradiotherapy; CT: computed tomography; ECOG: Eastern cooperative oncology group; FEV1: forced expiratory volume in 1 s; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression-free survival; PRs: partial responses; RECIST: response evaluation criteria in solid tumors; RILI: radiation-induced lung injury; VEGF: vascular endothelial growth factor.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
XJS and QHD carried out the studies and data analyses and drafted the manuscript. YXM and JYL carried out the sample collection and sample analyses. ZYD and JH participated in the design of the study and performed the statistical analysis. XJP conceived of the study, and participated in its design and coordination and helped to draft the manuscript. SLM designed, coordinated, and supervised the study and critically reviewed and discussed the manuscript. All authors have read and approved the final version of the manuscript.

Acknowledgements
We would like to thank Mrs. Shuiyun Han for her assistance in data retrieval and analyses. This work was sponsored in part by grants from Cancer Foundation of China key project (to Sheng-Lin Ma, No.1002) and Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents (to Ya-Ping Xu).

Author details
1Departments of Radiation Oncology, Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou 310022, China. 2Departments of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, China. 3Departments of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China. 4Departments of Medical Oncology, Zhejiang Hospital, Hangzhou 310013, China.

Received: 15 September 2014 Accepted: 1 March 2016
Published online: 11 April 2016

References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.
CA Cancer J Clin. 2011;61(2):69–90.
2. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692–9.
3. Curran Jr WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2001;103(19):1452–60.
4. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235(4787):442–7.
5. Folkman J. Endogenous inhibitors of angiogenesis. Harvey Lect. 1996;92:65–82.
6. Ge W, Cao DD, Wang HM, Jee FF, Zheng YF, Chen Y. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis. Asian Pac J Cancer Prev. 2011;12(10):2705–11.
7. Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, et al. A mutocenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(6):1104–9.
8. Zhao X, Mei K, Cai X, Chen J, Yu J, Zhou C, et al. A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Invest New Drugs. 2011;29(3):1144–9.
9. Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, et al. Endostatin improves radioreponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys. 2007;67(3):870–8.
10. Luo X, Slater JM, Gridley DS. Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model. Int J Radiat Oncol Biol Phys. 2005;63(2):553–64.
11. Englert S, Kieser M. Optimal adaptive two-stage designs for phase II cancer clinical trials. Biom J. 2013;55(6):955–68.
12. Wang L, Wu S, Ou G, Bi N, Li W, Ren H, et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2012;77(1):89–96.
13. Boehle AS, Kurdow R, Schulze M, Kliche U, Sipos B, Soondrum K, et al. Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer. 2001;94(3):420–8.
14. Iizasa T, Chang H, Suzuki M, Otsuji M, Yokoi S, Chiyo M, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res. 2004;10(16):5361–6.
15. Ni Q, Ji H, Zhao Z, Fan X, Xu C. Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism. Eur J Pharmacol. 2009614(1–3):1–6.
16. Patton JF, Spigel DR, Greco FA, Liggett WH, Zubkus LD, Baskette M, et al. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol. 2006;24(385a):7085).
17. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(1):43–8.
18. Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004;22(21):4341–50.

Submit your next manuscript to BioMed Central and we will help you at every step:
- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit